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REVIEW
Abstract: The role of glycoprotein (Gp) IIb/IIIa receptor antagonists remains controversial
and these agents are infrequently utilized during non-ST-segment elevation acute coronary
syndromes (NSTE-ACS) despite American Heart Association/American College of Cardiology
guidelines. Despite recommendations, the NRMI-4 (National Registry of Myocardial Infarction
4) and CRUSADE (Can rapid risk stratification of unstable angina patients suppress adverse
outcomes with early implementation of the ACC/AHA guidelines?) registries observed that
only 25%–32% of eligible patients received early Gp IIb/IIIa therapy, despite a 6.3% absolute
mortality reduction in NRMI-4 and a 2% absolute mortality reduction in CRUSADE. A pooled
analysis of Gp IIb/IIIa data from these registries suggest a major reduction in mortality (Odds
Ratio = 0.43, 95% Confidence Index 0.25–0.74, p = 0.002) with early Gp IIb/IIIa therapy, yet
clinicians fail to utilize this option in NSTE-ACS. The evidence-based approach to NSTE-
ACS involves aspirin, clopidogrel, low-molecular weight heparins, or unfractionated heparin
in concert with Gp IIb/IIIa receptor antagonists, however, newer percutaneous coronary
intervention (PCI)-based trials challenge current recommendations. Novel strategies emerging
in NSTE-ACS include omitting Gp IIb/IIIa inhibitors altogether or using Gp IIb/IIIa inhibitors
with higher doses of clopidogrel in selected patients. The ISAR-REACT (Intracoronary stenting
and antithrombotic regimen–Rapid early action for coronary treatment) and ISAR-SWEET
(ISAR–Is abciximab a superior way to eliminate elevated thrombotic risk in diabetics) trials
question the value of abciximab when 600 mg of clopidogrel concurrently administered during
PCI. The CLEAR-PLATELETS (Clopidogrel loading with eptifibatide to arrest the reactivity
of platelets) and PEACE (Platelet activity extinction in non-Q-wave MI with ASA, clopidogrel,
and eptifibatide) trials suggest more durable platelet inhibition when Gp IIb/IIIa inhibitors
are used with higher doses clopidogrel. The ISAR-COOL (ISAR: Cooling off strategy) trial
found no difference in ischemic outcomes when Gp IIb/IIIa inhibitors were excluded and
ARMYDA-2 (Antiplatelet therapy for reduction of myocardial damage during angioplasty)
suggested higher doses of clopidogrel are more appropriate during PCI when Gp IIb/IIIa
inhibitors are not utilized. This constellation of new trials forces reconsideration of current
recommendations in regards to patient risk stratification, choice of antithrombotic therapy,
doses, and timing. These new data will impact emerging guidelines and updates are currently
in progress.
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Introduction
The typical pharmacotherapeutic strategy for patients experiencing non-ST-segment
elevation acute coronary syndromes (NSTE-ACS) has been an intensive combination
of aspirin (ASA), clopidogrel, glycoprotein (Gp) IIb/IIIa inhibitor (abciximab,
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tirofiban, eptifibatide) along with an antithrombin
(unfractionated heparin [UFH] or low-molecular weight
heparin [LMWH]). Emerging clinical trials are challenging
the role of Gp IIb/IIIa-based strategies and suggesting new
options that differ by omitting Gp IIb/IIIa-based antiplatelet
therapeutics. A consequence of this new data has been a
variety of pharmacotherapeutic regimens that differ from
American Heart Association/American College of
Cardiology (ACC/AHA) guidelines, altering the established
timing and dosing of clopidogrel and challenging the utility
of Gp IIb/IIIa inhibitors by omitting them from the
antiplatelet regimen. This paper reviews the available
evidence to reinforce the best evidenced-based practices with
GP IIb/IIIa inhibitors and clopidogrel for patients
experiencing NSTE-ACS.
Pathophysiology
Platelet activation and the evolution of arterial thrombosis
are pivotal pathophysiologic events in ACS leading to
myocardial infarction (MI), urgent revascularization, stroke,
thrombotic embolization, and cardiovascular death. Early,
aggressive, antiplatelet therapy with Gp IIb/IIIa inhibitors
during ACS is endorsed by ACC/AHA and established by
extensive evidence from multiple prospective, randomized,
controlled trials. (CAPTURE 1997; EPILOG 1997;
IMPACT-II 1997; RESTORE 1997; PRISM 1998; PRISM-
PLUS 1998; PURSUIT 1998; ESPRIT 2000; Steinhubl et
al 2001; Braunwald et al 2002; Mahoney et al 2002).
Platelet activation during NSTE-ACS is driven by the
pathobiology of vascular injury, inflammation, and amplifi-
cation of the coagulation cascade. Vascular inflammation
and impaired endothelium-dependent vasodilatation are
regulated by a variety of cellular adhesion molecules
(CAMs) (Maksimowicz-McKinnon et al 2004). Vascular
cellular adhesion molecule-1 (VCAM-1) and intracellular
adhesion molecule-1 (ICAM-1) stimulates NAPDH oxidase,
which generates reactive oxygen species that alter
endothelial cell structure and facilitate leukocyte migration
into intracellular spaces (Iiyama et al 1999; Cook-Mills
2002; Maksimowicz-McKinnon et al 2004). P-selectin
mediates monocyte rolling and infiltration and platelet-
neutrophil interactions (Bhatt 2003).
Monocyte chemoattractant protein-1 (MCP-1) regulates
monocyte and macrophage migration and infiltration to sites
of active inflammation. MCP-1 further upregulates CAM
production and induces proinflammatory cytokines,
chemokines, and matrix metalloproteinases (MMPs) (Jiang
et al 1992; Yamamoto et al 2000). MCP-1 induces
proinflammatory interleukin-6 (IL-6) and promotes vascular
smooth muscle cell proliferation at inflamed plaques (Viedt
et al 2002). Activated T-cells and prothrombotic, pro-
inflammatory CD40–CD40L interactions trigger Gp IIb/IIIa
receptor expression on platelet surfaces. The concentration
of MMP-9 becomes elevated, which further destabilizes
vulnerable necrotic plaque by stimulating reactive oxygen
species, enhancing lipid peroxidation, and destroying
cellular membranes (Viedt et al 2002; Egashira 2003).
Proinflammatory, prothrombotic tumor necrosis factor-α
(TNF-α) and interleukin-1 (IL-1) modulates a variety of
functions including CAM expression, vascular smooth
muscle differentiation, MMP activation and further amplifies
the coagulation cascade (Ridker et al 2000; Sack 2002). This
progression facilitates atherosclerotic plaque rupture
exposing collagen and von Willebrand factor on the damaged
endothelium to create an extensive surface for platelet
adhesion. Adherent platelets subsequently aggregate,
following a release of a variety of platelet intracellular
signaling molecules including thromboxane A2(TxA2),
adenosine diphoshphate (ADP), serotonin (5-HT), and
epinephrine in addition to systemically circulating thrombin.
Additional platelets are recruited to the site of injury and
adhesion where conformational changes in platelet
cytoskeletal proteins result in upregulation and expression
of Gp IIb/IIIa receptors on platelet surfaces. Gp IIb/IIIa
receptor to fibrinogen-binding causes extensive cross-
linking, which facilitates thrombus formation. Considering
that multiple mechanisms are responsible for activating the
final common pathway of platelet activation, multiple
aggressive antithrombotic strategies are warranted to prevent
ischemic complications during percutaneous coronary
intervention (PCI). The Gp IIb/IIIa receptor target has been
the subject of many clinical trials, spirited debate, and
extensive controversy.
Gp IIb/IIIa receptor antagonists (abciximab, tirofiban,
eptifibatide) inhibit fibrinogen from cross-linking with
platelets which is the scaffold for thrombus growth and
formation. This “final common pathway” of Gp IIb/IIIa
receptor activation has been evaluated in several clinical
trials. (PRISM-PLUS 1998; PURSUIT 1998; ESPRIT 2000)
Small molecule Gp IIb/IIIa inhibitors (eptifibatide, tirofiban)
and chimeric antibody-based abciximab have fundamentally
different pharmacokinetics and pharmacodynamics which
only partially explain the variability observed during in-
vitro-platelet aggregometry and in-vivo outcomes data
(Batchelor et al 2002). Patients with diabetes have overtlyVascular Health and Risk Management 2006:2(1) 41
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accelerated platelet pathobiology, making the findings from
existing trials difficult to interpret and apply clinically. (Silva
and Gandhi 2004) Considering this challenge, guideline
endorsement of Gp IIb/IIIa inhibitors during ACS has varied
according to clinical features and ACS presentation. We
review the data to reinforce the best evidence-based
strategies for antiplatelet therapy during NSTE-ACS.
ACC/AHA recommendations for
small-molecule Gp IIb/IIIa
inhibitors in NSTE-ACS
NSTE-ACS
ACC/AHA recommendations for eptifibatide or tirofiban
during unstable angina (UA)/NSTE-ACS ACS are supported
by extensive clinical evidence (RESTORE 1997; PRISM-
PLUS 1998; PURSUIT 1998; ESPRIT 2000). A Gp IIb/IIIa
antagonist should be considered for patients with UA/NSTE-
ACS receiving ASA and UFH, scheduled for catheterization
and PCI. (Class Ia, grade A evidence) (Steinhubl et al 2001;
Braunwald et al 2002). Eptifibatide, in addition to ASA,
UFH or LMWH is also recommended for patients with
ongoing ischemia, elevated troponin, who are not candidates
for an invasive strategy. (Class IIa, grade A evidence)
(Braunwald et al 2002). Eptifibatide or tirofiban, in the
presence of clopidogrel, ASA and UFH in patients scheduled
for PCI has also been endorsed by the UA/NSTE-ACS
guidelines. (Class IIa, grade B evidence) (Braunwald et al
2002).
US registry data
In light of strong recommendations by the ACC/AHA
supported by extensive evidence from clinical trials, registry
data from CRUSADE and NRMI suggest that US practice
with Gp IIb/IIIa inhibitors is suboptimal. (Peterson et al
2003; Hoekstra et al 2005) The CRUSADE registry
consisted of 65 424 patients with NSTE-ACS across the US.
Early Gp IIb/IIIa inhibitor therapy was initiated in 35.5%
of the entire cohort. Among patients receiving a Gp IIb/IIIa
inhibitor, only 32% received early upstream Gp IIb/IIIa
therapy in the emergency department; 33% received therapy
in the coronary care unit; 32% received therapy in the
catheterization laboratory; and 3% elsewhere (Hoekstra et
al 2005). Comparing patients who received early Gp IIb/IIIa
with patients not receiving early therapy suggested that
patient features are predictive of the choice and timing of
therapy. Several patient features were associated with failure
to receive a Gp IIb/IIIa inhibitor including: females
(p < 0.0001), elevated heart rate (p < 0.0001), heart failure
(p < 0.0001), prior MI (p < 0.0001), prior hypertension
(p < 0.0001), prior stroke (p < 0.0001), renal insufficiency
(p < 0.0001), and Medicare/Medicaid coverage (p < 0.0001).
Males with hypercholesterolemia receiving care from
cardiologists were most likely to receive early Gp IIb/IIIa
therapy (p < 0.0001) (Hoekstra et al 2005). Patients in the
CRUSADE registry who received early Gp IIb/IIIa inhibitors
had 2% absolute reduction in overall mortality and a number
needed to treat (NNT) = 50. The NRMI-4 registry consisted
of 60 770 patients experiencing NSTE-ACS across the US
(Peterson et al 2003). Only 25% received early Gp IIb/IIIa
within 24 hours of presentation. A consistent pattern of
similar characteristics predicted failure to use Gp IIb/IIIa
inhibitors in the NRMI-4 registry: females (p < 0.0001),
increasing age (p < 0.0001), prior stroke (p < 0.0001), prior
peripheral vascular disease (p = 0.004), and nonwhite status
(p < 0.0001) (Peterson et al 2003). Patients in the NRMI-4
receiving Gp IIb/IIIa inhibitor experienced a 6.3% absolute
reduction of in-hospital mortality with a NNT = 16. Taken
together, a pooled analysis of the CRUSADE and NRMI-4
data suggests that early Gp IIb/IIIa inhibitor therapy is
associated with a reduction in crude rate of mortality (Odds
ratio [OR] = 0.43; 95% Confidence interval [CI] 0.25–0.74;
p = 0.002) (Figure 1). The complicated and evolving
presentation of NTSE-ACS is difficult to evaluate and may
explain the failure to use early Gp IIb/IIIa therapy.
Appropriate selection of pharmacotherapy requires a careful
evaluation of risks, clinical features, and patient
characteristics most associated with benefits. Possible
options to assist with this evaluation are the use of TIMI
(Thrombolysis in MI)-risk scores or NRMI–NSTE-ACS risk
scores as guides for Gp IIb/IIIa selection.
Established evidence – the foundation
of guideline recommendations
Several trials have demonstrated increased inhibition of
platelet aggregation with the cocktail of antiplatelet–
antithrombin combinations used in the ESPRIT, CLEAR-
PLATELETS, and PEACE (Platelet activity extinction in
non-Q-wave MI with ASA, clopidogrel, and eptifibatide)
trials. Pharmacodynamic evaluations of eptifibatide in the
doses used in the IMPACT II and PURSUIT trials suggested
< 80% platelet inhibition; a dose which is less than optimal
for protection against occlusive thrombus formation. These
pharmacodynamic findings are still considered unfavorable
despite a 2.5% absolute reduction (p = 0.035) in 30-dayVascular Health and Risk Management 2006:2(1) 42
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death, MI, or urgent revascularization in IMPACT II and
1.5% absolute reduction (p = 0.04) in death or MI in
PURSUIT. The ESPRIT trial used a high dose, double-bolus/
infusion regimen of 180/2/180 (180 µg bolus of eptifibatide
followed by a 2 µg/kg/min infusion for 18–24 hours with
second 180 µg bolus within 10 minutes of the first bolus) or
placebo along with ASA, clopidogrel, and weight-adjusted
UFH. The trial was designed to uniformly achieve > 80%
platelet inhibition and reduce ischemic complications. The
primary endpoint was 48-hour death, MI, revascularization,
or thrombotic bailout. ESPRIT was powered to achieve a
33% reduction in 30-day death, MI, or revascularization
(1-β = 0.86; two-tailed-α = 0.05). Patients receiving
eptifibatide had a 3.9% absolute reduction (NNT = 26;
p = 0.015) of death, MI, revascularization, or thrombotic
bailout at 48-hours and a 3.7% absolute reduction
(NNT = 29; p = 0.0034) in 30-day death, MI, or
revascularization. The majority of ischemic events (88%)
occurred within 48 hours of PCI suggesting that antiplatelet
therapy should be maximized early within the first 48 hours
after PCI. Reductions in these short-term composite
endpoints are largely driven by the reduction of small, non-
Q-wave MI. Large MI, death, and urgent revascularization
were not different between eptifibatide or placebo in
ESPRIT. Among patients receiving the eptifibatide double-
bolus/infusion, 90% achieved 90% platelet inhibition using
standard platelet aggregometry. A long-term follow up in
the ESPRIT cohort revealed a 4.4% absolute reduction in
death or MI at 12 months (NNT = 23) and a 3.6% absolute
reduction in death, MI, or revascularization at 12 months
(NNT = 28) (O’Shea et al 2002). The mechanism by which
a short-acting, small molecule glycoprotein IIb/IIIa inhibitor
administered at the time of PCI protects against death, MI,
and revascularization at 12-months is unknown, yet the
benefits are documented. Thus, eptifibatide 180/2/180
double bolus reduced both short-term and long ischemic
outcomes and produced durable, predictable platelet
inhibition in a contemporary study design where clopidogrel
bolus and maintenance doses were used with a variety of
different stents.
Pooling all data from the PRISM, PRISM-PLUS,
PURSUIT, GUSTO IV (Effect of glycoprotein IIb/IIIa
receptor blocker abciximab on outcome in patients with
acute coronary syndromes without early coronary
revascularization: the GUSTO IV-ACS randomized trial),
PARAGON (platelet IIb/IIIa antagonism for the reduction
of acute coronary syndrome events in a global organization
network) A, and PARAGON B trials in patients with NSTE-
ACS receiving medical management suggested that
Gp IIb/IIIa inhibition is associated with early reduction in
mortality at 30 days (absolute risk reduction [ARR] = 1.6%;
NNT = 63) among patients with diabetes, but no
corresponding reduction in mortality was observed among
patients without diabetes. (Roffi et al 2001) Further analysis
of the GUSTO IV trial alone suggested that medical
management of NSTE-ACS with abciximab is not beneficial
at 30 days, thus benefit seen in previous meta-analysis were
driven by small-molecule Gp IIb/IIIa inhibitors rather than
abciximab (Simoons et al 2001).
Emerging trials
Current and emerging trials introduce new strategies to
intervene against early thrombosis and ischemic outcomes
in NSTE-ACS, however, the results are confusing since the
heterogeneity of patients, methods, and endpoints creates
difficulty in extrapolating outcomes data to patients
presenting to the catheterization laboratory of most
institutions. Confusion extends into questions regarding
Figure 1 Evaluation of mortality among patients receiving early Gp/IIb/IIIa inhibitors in US National Registeries.
Early Gp IIb/IIIa inhibitor is better                     No Gp IIb/IIIa inhibitor is betterVascular Health and Risk Management 2006:2(1) 43
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patient selection, urgent or elective PCI, and choice of
pharmacotherapy. ACC/AHA guideline-directed inter-
ventions in the case of urgent or elective PCI include the
early use of ASA to antagonize TxA2 mediated platelet
activation, 300 mg clopidogrel loading dose prior to PCI
followed by 75 mg maintenance dosing afterward, targeting
ADP-mediated P2Y12 platelet surface receptors, LMWH-,
or UFH-based antithrombin strategies and the use of either
eptifibatide or abciximab to block platelet Gp IIb/IIIa
receptors on the platelet surface (Braunwald et al 2002).
Radical trial designs in progress are evaluating the extent
of platelet inhibition and ischemic endpoints in the absence
of Gp IIb/IIIa-based strategies opting for larger doses of
clopidogrel or the use of bivalrudin to achieve platelet
inhibition. These strategies may cause confusion in drug
selection and undermine previous research that demon-
strated robust and durable platelet inhibition when
combinations of ASA, clopidogrel, LMWH, or UFH and a
Gp IIb/IIIa inhibitor are selected.
Clopidogrel alone or in combination
with Gp IIb/IIIa inhibitors
The ISAR (Intracoronary stenting and antithrombotic
regimen) trials examined the necessity of Gp IIb/IIIa
inhibitors in coronary artery disease in varying patient
populations, settings and pharmacotherapeutic regimens
(Kandzari et al 2004; Mehilli et al 2004). ISAR-REACT
(ISAR-Rapid early action for coronary treatment) deter-
mined the benefit of abciximab in low-risk patients
undergoing elective PCI after pretreatment with clopidogrel
(Kandzari et al 2004). Patients were excluded if they
experienced a MI within 14 days, unstable angina with
electrocardiographic changes, positive biomarkers,
thrombus percentage, lesions in bypass grafts, left
ventricular ejection fraction of less than 30%, insulin-
dependent diabetes mellitus, hemodynamic instability,
stroke in the past 3 months, and pericarditis. In a double-
blind-fashion, patients were randomized to abciximab
(n = 1079) or to placebo (n = 1080). All patients were
pretreated at least two hours before PCI with 325 mg–500 mg
of ASA and 600 mg of clopidogrel. Larger doses of UFH
were administered to the placebo group (140 U/kg) than to
the abciximab group (70 U/kg). Post-PCI patients received
100 mg–325 mg of ASA, clopidogrel 75 mg twice daily for
three days or until discharge and then once daily thereafter,
and any other cardiac medications as prescribed. The
primary endpoint was the cumulative incidence of all-cause
mortality, MI, or urgent revascularization at 30 days. The
event rate was lower than initially predicted and
subsequently, the sample size of the trial was doubled in an
attempt to demonstrate a 40% reduction in the occurrence
of the primary endpoint. The frequency of the primary
endpoint at 30 days was 4% in both groups (Relative risk
[RR] associated with abciximab: 1.05; 95% CI, 0.69–1.59;
p = 0.82) (Kandzari et al 2004). There was no significant
difference between abciximab and placebo in regards to
major or minor bleeding events (p = 0.37 and p = 0.38,
respectively). There was a greater occurrence of thrombo-
cytopenia and blood transfusions in the abciximab group
(p = 0.002 and p = 0.007, respectively). The authors
concluded no clinical benefit was observed with abciximab
within 30 days of PCI. This trial raises the question of
omitting Gp IIb/IIIa receptor blockade, at least with
abciximab in selected patients, since there was no difference
in all-cause mortality, MI, or 30-day revascularization, nor
were there differences in bleeding. There are several
limitations to consider. The patient population studied in
the ISAR-REACT is generally not the population that
receives Gp IIb/IIIa inhibitors. Previous studies demon-
strated that intermediate-to-high-risk patients requiring PCI
receive the most benefit from these agents (EPIC 1994;
PRISM-PLUS 1998; PURSUIT 1998; ESPRIT 2000;
Steinhubl et al 2001; Topol et al 2001; Braunwald et al 2002).
In essence, ISAR-REACT is an underpowered study that
suggests low-to-moderate risk patients undergoing elective
PCI after pretreatment with 600 mg of clopidogrel do not
receive additional benefit from abciximiab and would further
imply that Gp IIb/IIIa inhibitors are best reserved for
moderate-to-high risk patients requiring PCI. This
suggestion reinforces the need for careful risk stratification
when selecting antithrombotic regimens.
In contrast, the ISAR-SWEET (ISAR: Is abciximab a
superior way to eliminate elevated thrombotic risk in
diabetics) trial determined if abciximab provides benefit in
diabetic patients after pretreatment with 600 mg of
clopidogrel and 500 mg of ASA at least two hours before
elective PCI (Mehili et al 2004). Patients were excluded by
similar criteria as in ISAR-REACT trial with the exception
of diabetes mellitus. In a randomized double-blind fashion,
patients received abciximab (n = 351) or placebo (n = 350)
along with UFH, ASA, and clopidogrel as in ISAR-REACT
(Kandzari et al 2004). No statistical difference was observed
between groups in the primary composite endpoint of all-
cause mortality and MI at one year (8.3% in the abciximab
group vs 8.6% in the placebo group; p = 0.91) (Mehili et alVascular Health and Risk Management 2006:2(1) 44
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2004). Unlike the ISAR-REACT trial, there were no
significant differences relative to major (p = 0.99) or minor
(p = 0.09) bleeding events, blood transfusions (p = 0.11), or
thrombocytopenia (p = 0.12). These results should be
interpreted cautiously. Although the patient population
included patients with diabetes, these patients were not high-
risk because they had acceptable glycemic control as
reflected by an estimated mean hemoglobin A1c of 7.1%,
but they were excluded if they had ACS, and the mean
ejection fraction was 55%. Furthermore, the management
practice patterns are in stark contrast to practice in the US.
This is exemplified by the dose of UFH and clopidogrel,
and that only 10% of the patients received drug-eluting stent.
Most importantly, there was an 11% loss in statistical power
(reduction in power from 80% to 69%) which was attributed
to unexpectedly lower event rates in the placebo group
(expected event rate of 14% vs the actual event rate of 8%).
The ISAR trials evaluated low-risk patients undergoing
elective PCI and this is not representative of the ACC/AHA
recommendations or US registry data. A clinical trial
observed that a Gp IIb/IIIa based therapy was not associated
with fewer instances of all-cause mortality and MI at 30
days with equivocal bleeding risk. Some early interpretations
suggest omitting Gp IIb/IIIa antiplatelet agents in select
patients undergoing PCI. Considering early data with
abciximab–clopidogrel combinations, there has been some
equivocal evidence in regards to ischemic outcomes in small
trials. It is not valid to assume the same equivalence when
considering eptifibatide or tirofiban since these combinations
have not been evaluated under similar protocols and
abciximab has never been shown to be superior to
eptifibatide or tirofiban in head-to-head trials based on
outcomes data.
The CLEAR-PLATELETS study was the largest
pharmacodynamic comparison to date evaluating platelet
aggregation in response to 300 mg or 600 mg of clopidogrel
with and without eptifibatide in the setting of PCI.
Investigators evaluated the extent of antiplatelet activity of
300 mg or 600 mg clopidogrel alone and in the presence of
eptifibatide dosed according to the ESPRIT 180/2/180
protocol (ESPRIT 2000; Gurbel et al 2005). Patients
received ASA 81 mg, UFH 60 U/kg bolus prior to PCI.
Clopidogrel-based strategies in the absence of eptifibatide
may not be sufficient to provide adequate antiplatelet
protection alone. Previous pharmacodynamic studies have
indicated that a clopidogrel 300 mg dose achieves 40%
platelet inhibition within 8–18 hours of the loading dose.
Eptifibatide dosing according to the ESPRIT protocol
routinely achieves  ≥ 80% platelet inhibition (Gurbel et al
2002). Patients receiving clopidogrel and eptifibatide had
consistently greater platelet inhibition at 18 and 24 hours
compared with those receiving clopidogrel alone (p = 0.001)
(Gurbel et al 2005). Clopidogrel in the absence of
eptifibatide does not produce adequate platelet inhibition at
either 300 mg or 600 mg doses. Those receiving 300 mg of
clopidogrel alone achieved approximately 20% platelet
inhibition at 18–24 hours in response to physiologic
concentrations of 20 µM ADP. A 600 mg dose alone results
in < 35% platelet inhibition at 18–24 hours in response to
20 µM ADP. Only patients receiving eptifibatide in addition
to clopidogrel were able to consistently achieve platelet
inhibition of ≥ 80% at 18–24 hours. Patients receiving
600 mg of clopidogrel and eptifibatide had greater platelet
inhibition compared with those receiving 300 mg of
clopidogrel and eptifibatide (p = 0.05) Thus, patients
receiving higher doses of clopidogrel achieve greater
platelet inhibition with and without eptifibatide. Patients
receiving clopidogrel  and  eptifibatide  achieve  approxi-
mately ≥ 2-fold greater platelet inhibition compared with
clopidogrel alone. Patients receiving clopidogrel 600 mg or
300 mg in conjunction with eptifibatide had less Gp IIb/IIIa
receptor expression at 18–24 hours after stent placement
(p ≤ 0.05). Patients receiving clopidogrel and eptifibatide had
less troponin-I (p = 0.04), myoglobin (p = 0.02), and CKMB
(p = 0.05) release. A higher dose of clopidogrel (600 mg)
plus eptifibatide offers better platelet inhibition, less
Gp IIb/IIIa expression, and limits the extent of myocardial
necrosis better than a 300 mg loading-dose of clopidogrel
with and without eptifibatide. Thus, in the setting of elective
PCI the combination of clopidogrel–eptifibatide may
provide more protection against myocardial necrosis and
ischemia compared with clopidogrel alone without a Gp
IIb/IIIa inhibitor. The limitation to CLEAR PLATELETS
was its design as a pharmacodynamic investigation using
platelet aggregometry and markers of myocardial necrosis
rather than true ischemic outcomes. These pharmaco-
dynamic findings suggest that a combination of clopidogrel–
eptifibatide may offer greater protection against ischemic
outcomes.
The PEACE trial further supports the necessity of
multidrug antiplatelet therapy during NSTE-ACS (Dalby
et al 2004). PEACE evaluated the differences in Gp IIb/IIIa
receptor expression and fibrinogen binding between patients
receiving eptifibatide–clopidogrel or clopidogrel mono-
therapy among 32 people experiencing NSTE-ACS. All
patients received ASA 500 mg intravenous followed byVascular Health and Risk Management 2006:2(1) 45
Platelet inhibitors in non-ST elevation ACS
75 mg daily, enoxaparin 1 mg/kg subcutaneous twice daily,
and other cardiac medications as deemed appropriate.
Platelet activation was assessed at baseline (ASA and
enoxaparin only), 3 hours after a 300 mg loading-dose of
clopidogrel, and then 12 hours after the initiation of the
eptifibatide infusion (180 µg/kg bolus, followed by 2 µg/kg/
minute infusion) which was immediately administered
before cardiac catheterization. Greater reductions in Gp IIb/
IIIa receptor expression were observed in the eptifibatide/
clopidogrel group when ADP (48% vs 80%; p < 0.0001) or
thrombin receptor-activating peptide (43% vs 78%,
p < 0.001) was used to activate platelets (Dalby et al 2004).
Using the same platelet agonists, fibrinogen binding was
significantly reduced with eptifibatide and clopidogrel, then
with clopidogrel monotherapy (p < 0.001). These data
suggest that the combination of eptifibatide–clopidogrel
provides greater antiplatelet activity than clopidogrel alone.
Clopidogrel pretreatment or post-
treatment?
In a randomized controlled trial, ISAR-COOL (ISAR:
Cooling off strategy) evaluated the outcomes of prolonged
antithrombotic pretreatment (3–5 days) to early intervention
(less than six hours) prior to PCI in 410 patients with ACS.
All patients received UFH 60 U/kg bolus followed by a
continuous infusion adjusted to maintain partial
thromboplastin time of 60–85 seconds, ASA 500 mg
intravenous bolus followed by 100 mg twice daily oral dose,
clopidogrel 600 mg loading dose followed by 75 mg twice
daily, and tirofiban 10 µg/kg bolus followed by a continuous
infusion of 0.10 µg/kg/minute. Eligibility criteria included:
angina at rest, angina with minimal exertion, and either
positive troponin or ST-segment changes. The primary
endpoint was the 30-day composite of all–cause mortality
and MI. A statistical difference was observed between
groups at 30 days (RR 1.96; 95% CI (1.01–3.82), p = 0.05)
(Kandzari et al 2004). Early intervention was superior to
prolonged antithrombotic pretreatment. The tirofiban dose
used in this study was found to be suboptimal as evidenced
in  TARGET  (Do  Tirofiban  and  ReoPro give similar
efficacy trial) (Steinhubl et al 2001). Caution is warranted
when extrapolating conclusions that clopidogrel is more
beneficial than Gp IIb/IIIa inhibitors in this context;
considering that a major difference between treatment arms
in the ISAR-COOL was time-to-catheterization in addition
to different pharmacotherapeutic strategies. The ISAR trials
propose this controversy, questioning whether clopidogrel,
Gp IIb/IIIa inhibitor, or both, are warranted.
Variability in response to the antiplatelet activity of
clopidogrel may result in a higher proportion of thrombotic
events and recurrent ischemia in nonresponders; a
pharmacodynamic problem likely to be overcome in this
minority of patients with higher doses of clopidogrel (Müller
et al 2003; Lau et al 2004). Contemporary 300 mg doses of
clopidogrel 6 hours prior to PCI when used in conjunction
with ASA, UFH, or LMWH and eptifibatide, may still lead
to early in-stent thrombosis and periprocedural ischemia
(Patti et al 2005). Periprocedural ischemia occurs within
the first 8 hours of PCI, and more commonly among patients
in the highest quartiles of postprocedural platelet reactivity
(Saucedo et al 2005). The differences in platelet reactivity,
patient variability, and insufficient metabolite production
may be overcome with increasing doses of clopidogrel.
Loading-doses of 600 mg may provide improved antiplatelet
activity over 300 mg doses alone or in the presence of Gp
IIb/IIIa inhibitor-based therapy. A 600 mg loading dose of
clopidogrel provides better early inhibition at 2 hours
compared with 300 mg doses and peak inhibitory effects of
30%–50% platelet inhibition occurs at 8 hours with 600 mg
doses compared with patients receiving 300 mg loading
doses who have peak inhibitory effects between 8–18 hours
(Gurbel et al 2005).
Clopidogrel loading-dose and insufficient metabolite
production are related reasons for observed post-treatment
platelet aggregation. Defining clopidogrel “responders” and
“nonresponders” may help direct drug therapy. The
relationship between clopidogrel loading-dose and
responsiveness has been studied in a cohort of 190 patients
undergoing elective coronary stenting randomized to either
300 mg or 600 mg of clopidogrel immediately after stent
placement (Gurbel et al 2002). A 600 mg load was associated
with greater changes in platelet aggregation inhibition in
response to either 5 µM ADP (30% vs 20%, p < 0.001) or
20 µM ADP (29% vs 16%, p < 0.001). More patients
responded to 600 mg of clopidogrel at 5 µM ADP (35% vs
20%, p = 0.03) and at 20 µM ADP (37% vs 21%, p = 0.02).
Across increasing tertiles of post-treatment platelet
aggregation, the 600 mg loading-dose was consistently
associated with fewer nonresponders, even in the group with
the highest post-procedural platelet aggregation (6% vs
17%), suggesting overall improved antiplatelet activity
across all groups and a reduction in the proportion of patients
not responding to clopidogrel. The limitations to this data
set were that recent Gp IIb/IIIa inhibitor use was considered
criteria for exclusion and ischemic outcomes data were not
part of the study design.Vascular Health and Risk Management 2006:2(1) 46
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The ARMYDA-2 (Antiplatelet therapy for reduction of
myocardial damage during angioplasty) trial randomized
255 patients with NSTE-ACS to 600 mg or 300 mg of
clopidogrel within 4–8 hours of PCI and evaluated 30-day
death, MI, or revascularization (Patti et al 2005). Gp IIb/IIIa
receptor use and choice of stent were left to the operator’s
discretion. Though ARMYDA-2 was a small clinical trial,
an impressive 8% absolute reduction of 30-day death, MI,
or revascularization (p = 0.041, NNT = 13) was observed in
the group randomized to 600 mg of clopidogrel.
Periprocedural myocardial ischemia was measured by
evaluating postprocedural creatinine kinase MB isoenzyme,
troponin I, and myoglobin release. The 600 mg dose of
clopidogrel was associated with significant reductions in
all postprocedural biomarkers and high-dose clopidogrel
was independently predictive of decreased risk of
periprocedural MI in a related multivariate analysis (OR
0.48, 95% CI 0.15–0.97; p = 0.044) (Patti et al 2005).
Considering that data exists suggesting benefit of 600 mg
of clopidogrel prior to PCI and after PCI, the debate now
extends to optimal timing of clopidogrel in patients
experiencing NSTE-ACS. Early treatment with clopidogrel
reduces early ischemic events, provides benefit among those
ultimately receiving PCI, but increases risk of bleeding if
coronary anatomy is unknown, and coronary artery bypass
grafting (CABG) is a possibility (Mehta et al 2001; Yusuf
et al 2003). Approximately 50%–60% of those presenting
with ACS will receive PCI and 8%–20% would be
considered for CABG (Cannon 2005). Delaying clopidogrel
minimizes bleed risks for the minority of CABG patients
and benefit or reducing early ischemia, and treatment
benefits are lost for the majority proceeding to PCI.
Selective, early identification of patients who may need
urgent CABG using TIMI risk score tools may help identify
those who should not receive early 600 mg clopidogrel
loading-doses, minimizing bleeding risk of those proceeding
to CABG, and preserving benefit for the majority requiring
PCI (Cannon 2005).
Summary
Pharmacotherapeutic approaches to NSTE-ACS requiring
PCI are complicated by a myriad of evolving antiplatelet
strategies that have existed experimentally and outside our
current evidence-driven guidelines. Optimal use of Gp IIb/IIIa
receptor antagonists involves identifying the appropriate
window for therapy, drug choice, appropriate dosing, and
patient selection. Heterogeneity in clinical trials has borne
a mix of data suggesting both benefit and equivalence
making interpretation difficult for both clinical and
interventional cardiologists. Higher-risk patients with
NSTE-ACS requiring PCI are most likely to achieve benefit
from Gp IIb/IIIa receptor antagonists when they have
ongoing ischemia, dynamic EKG changes, and positive
troponins due to unstable plaque with active inflammation.
Gp IIb/IIIa receptor blockade limits ischemic complications
of PCI across all indications, among various devices,
throughout multiple anticoagulation approaches using a
variety of agents. Future guidelines should provide more
specific direction regarding risk stratification in an era where
Gp IIb/IIIa receptor blockade and clopidogrel may be used
in concert in NSTE-ACS and PCI.
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